We Power Antibody Discovery

  • Adagene Presents Its Lead Antibody Program, ADG106, at International Conferences

  • Adagene and ADC Therapeutics Announce SAFEbodyTM License Agreement

QUALITY BY DESIGN
Read more
BEYOND MOTHER NATURE
Read more
ABOUT ADAGENE

Adagene (Suzhou China) is a clinical stage biotech company with innovative antibody discovery and engineering technologies. Utilizing its proprietary Dynamic Precision Library Platform (DPL), Adagene is developing immuno-oncology antibodies against novel epitopes that give unique product profiles that have potential to succeed where other groups have failed.
Adagene is showcasing its exceptional antibody engineering capabilities by building franchises of products with multi-specific antibodies that are cross-species reactive to accurately find the correct structural relationship and drug combinations to find the ideal therapeutic. Also, Adagene is developing a third-generation technology to enhance the therapeutic window for antibodies.
Adagene has received notification from the FDA to proceed on its IND application to study its lead product in patients with advanced solid tumors and non-Hodgkin lymphoma which exhibits robust single agent and combination activity in multiple pre-clinical models. Adagene’s second and third products are currently anticipated filing global INDs in 2019 and 2020.
The company’s management team is composed of industry veterans with proven track record in therapeutic antibody R&D. Adagene is backed by top notch global venture funds such as F-Prime Capital Partners, Eight Roads Ventures, 6 Dimensions Capital, GP Healthcare Capital, New World TMT Ltd and Sequoia China. The company has raised over $100 million through its series A to C financing.

Suzhou.China
NEWS
Adagene Presents Its Lead Antibody Program, ADG106, at International Conferences

An overview of Adagene’s Dynamic Precision Antibody Library system and a case study of its leading clinical program ADG106, a fully human anti-CD137 agonistic antibody, was orally presented at the Festival of Biologics.
Clinical data of the Phase 1 first in human study will be presented at AACR-NCI-EORTC on Sunday, Oct. 27th2019.

2019.10.26
©Copyright-Adagene 2019